Comparing ε-Aminocaproic Acid and Tranexamic Acid in Reducing Postoperative Transfusions in Total Knee Arthroplasty

Abstract

Multiple studies have shown tranexamic acid (TXA) to reduce blood loss and transfusion rates in patients undergoing total knee arthroplasty (TKA). Accordingly, TXA has become a routine blood conservation agent for TKA. In contrast, ε-aminocaproic acid (EACA), a similar acting antifibrinolytic to TXA, has been less frequently used. This study evaluated whether EACA is as efficacious as TXA in reducing postoperative blood transfusion rates and compared the cost per surgery between agents. A multicenter retrospective chart review of elective unilateral TKA from April 2012 through December 2014 was performed. Five hospitals within a health care system participated. Data collected included age, gender, severity of illness score, use of antifibrinolytic and dose, red blood cell (RBC) transfusions and the number of units, and preadmission and discharge hemoglobin (Hb). Dosing of the antifibrinolytic differed based on the agent used, 5 or 10 g (based on weight) for EACA versus 1 g for TXA. The institutional acquisition cost of each antifibrinolytic was obtained and averaged over the study period. Of 2,922 primary unilateral TKA cases, 820 patients received EACA, 610 patients received TXA, and 1,492 patients received no antifibrinolytic (control group). Compared with the control group both EACA and TXA groups had significantly fewer patients transfused (EACA 2.8% [p < 0.0001], TXA 3.2% [p < 0.0001] vs. control 10.8%) and lower mean RBC units transfused per patient (EACA 0.05 units/patient [pt] [p < 0.0001], TXA 0.05 units/pt [p < 0.0001] vs. control 0.19 units/pt]. There was no difference in mean RBC units transfused per patient, percentage of patients transfused, and discharge Hb levels between the EACA and TXA groups (p = 0.822, 0.236, and 0.322, respectively). Medication acquisition cost for EACA averaged $2.23 per surgery compared with TXA at $39.58 per surgery. Administration of EACA or TXA significantly decreased postoperative transfusion rates compared with no antifibrinolytic therapy. Utilization of EACA for unilateral TKA proved to be comparable to TXA in all studied aspects at a lower cost. The level of evidence for the study is Level 3.

Keywords

total knee arthroplasty - total joint arthroplasty - tranexamic acid - ε-aminocaproic acid - blood transfusion

• References

• 1 Ponnusamy KE, Kim TJ, Khanuja HS. Perioperative blood transfusions in orthopaedic surgery. J Bone Joint Surg Am 2014; 96 (21) 1836-1844
• 2 Bierbaum BE, Callaghan JJ, Galante JO, Rubash HE, Tooms RE, Welch RB. An analysis of blood management in patients having a total hip or knee arthroplasty. J Bone Joint Surg Am 1999; 81 (01) 2-10
• 3 Hart A, Khalil JA, Carli A, Huk O, Zukor D, Antoniou J. Blood transfusion in primary total hip and knee arthroplasty. Incidence, risk factors, and thirty-day complication rates. J Bone Joint Surg Am 2014; 96 (23) 1945-1951
• 4 Chen AF, Klatt BA, Yazer MH, Waters JH. Blood utilization after primary total joint arthroplasty in a large hospital network. HSS J 2013; 9 (02) 123-128
• 5 Nadeau RP, Howard JL, Naudie DDR. Antifibrinolytic therapy for perioperative blood conservation in lower-extremity primary total joint arthroplasty. JBJS Rev 2015; 3 (06) e1
• 6 Kim TK, Chang CB, Koh IJ. Practical issues for the use of tranexamic acid in total knee arthroplasty: a systematic review. Knee Surg Sports Traumatol Arthrosc 2014; 22 (08) 1849-1858
• 7 Gillette BP, Maradit Kremers H, Duncan CM. , et al. Economic impact of tranexamic acid in healthy patients undergoing primary total hip and knee arthroplasty. J Arthroplasty 2013; 28 (8, Suppl): 137-139
• 8 Vigna-Taglianti F, Basso L, Rolfo P. , et al. Tranexamic acid for reducing blood transfusions in arthroplasty interventions: a cost-effective practice. Eur J Orthop Surg Traumatol 2014; 24 (04) 545-551
• 9 Fingar KR, Stocks C, Weiss AJ, Steiner CA. Most Frequent Operating Room Procedures Performed in U.S. Hospitals, 2003–2012. .HCUP Statistical Brief #186. December 2014. Available at: http://www.hcup-us.ahrq.gov/reports/statbriefs/sb186-Operating-Room-Procedures-United-States-2012.pdf . Accessed September 12, 2016.
• 10 3M HIS APRTM-DRG. Classification Software–Overview. Available at: http://archive.ahrq.gov/professionals/quality-patient-safety/quality-resources/tools/mortality/Hughessumm.pdf . Accessed July 5, 2016
• 11 Kiridly DN, Karkenny AJ, Hutzler LH, Slover JD, Iorio R, Bosco III JA. The effect of severity of disease on cost burden of 30-day readmissions following total joint arthroplasty (TJA). J Arthroplasty 2014; 29 (08) 1545-1547
• 12 Chauhan S, Gharde P, Bisoi A, Kale S, Kiran U. A comparison of aminocaproic acid and tranexamic acid in adult cardiac surgery. Ann Card Anaesth 2004; 7 (01) 40-43
• 13 Falana O, Patel G. Efficacy and safety of tranexamic acid versus ε-aminocaproic acid in cardiovascular surgery. Ann Pharmacother 2014; 48 (12) 1563-1569
• 14 Makhija N, Sarupria A, Kumar Choudhary S, Das S, Lakshmy R, Kiran U. Comparison of epsilon aminocaproic acid and tranexamic Acid in thoracic aortic surgery: clinical efficacy and safety. J Cardiothorac Vasc Anesth 2013; 27 (06) 1201-1207
• 15 Camarasa MA, Ollé G, Serra-Prat M. , et al. Efficacy of aminocaproic, tranexamic acids in the control of bleeding during total knee replacement: a randomized clinical trial. Br J Anaesth 2006; 96 (05) 576-582
• 16 Tan J, Chen H, Liu Q, Chen C, Huang W. A meta-analysis of the effectiveness and safety of using tranexamic acid in primary unilateral total knee arthroplasty. J Surg Res 2013; 184 (02) 880-887
• 17 Wei Z, Liu M. The effectiveness and safety of tranexamic acid in total hip or knee arthroplasty: a meta-analysis of 2720 cases. Transfus Med 2015; 25 (03) 151-162
• 18 Duncan CM, Gillette BP, Jacob AK, Sierra RJ, Sanchez-Sotelo J, Smith HM. Venous thromboembolism and mortality associated with tranexamic acid use during total hip and knee arthroplasty. J Arthroplasty 2015; 30 (02) 272-276
• 19 ClinicalTrials.gov. TXA vs. Amicar in Total Knee and Hip Arthroplasty. Available at: https://clinicaltrials.gov/ct2/show/NCT02030821 . Accessed June 27, 2016